Epinastine ophthalmic - Allergan

Drug Profile

Epinastine ophthalmic - Allergan

Alternative Names: 0.05% epinastine ophthalmic solution; Alesion Ophthalmic Solution; DE-114; Elestat; Epinastine eye drops; Epinastine hydrochloride; Purivist; Relestat

Latest Information Update: 29 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Allergan; Santen Pharmaceutical
  • Class Antiallergics; Dibenzazepines; Imidazoles; Nonsedating antihistamines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Histamine H2 receptor antagonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic conjunctivitis

Most Recent Events

  • 01 May 2017 Phase-III clinical trials in Allergic conjunctivitis (In adolescents, In adults) in Japan (Ophthalmic) (JapicCTI173622)
  • 01 May 2017 Phase-III clinical trials in Allergic conjunctivitis in Japan (Ophthalmic) (JapicCTI-173579)
  • 25 Nov 2013 Launched for Allergic conjunctivitis in Japan (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top